Annexon Inc.

1.90-0.1900-9.09%Vol 518.56K1Y Perf -68.24%
Oct 4th, 2023 16:00 DELAYED
BID1.85 ASK1.99
Open2.02 Previous Close2.09
Pre-Market- After-Market1.96
 - -  0.06 3.16%
Target Price
18.57 
Analyst Rating
Moderate Buy 1.63
Potential %
877.37 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/-20 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/89 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/98 
Income Ranking
 —    -
Price Range Ratio 52W %
-1.41 
Earnings Rating
Market Cap101.15M 
Earnings Date
2nd Nov 2023
Alpha-0.03 Standard Deviation0.24
Beta0.69 

Today's Price Range

1.902.10

52W Range

1.987.65

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-17.03%
1 Month
-29.10%
3 Months
-46.93%
6 Months
-52.74%
1 Year
-68.24%
3 Years
-93.15%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANNX1.90-0.1900-9.09
AAPL173.661.26000.73
GOOG136.272.97002.23
MSFT318.965.56501.78
XOM111.50-4.3300-3.74
WFC38.970.30000.78
JNJ155.520.18000.12
FB196.640.99000.51
GE108.851.09001.01
JPM143.350.64000.45
Financial StrengthValueIndustryS&P 500US Markets
13.30
13.60
0.11
0.13
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.54-0.4712.96
Q01 2023-0.52-0.520.00
Q04 2022-0.52-0.487.69
Q03 2022-0.87-0.5141.38
Q02 2022-0.94-0.96-2.13
Q01 2022-1.00-0.928.00
Q04 2021-0.90-0.97-7.78
Q03 2021-0.88-0.93-5.68
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.50
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume518.56K
Shares Outstanding53.24K
Shares Float32.39M
Trades Count5.27K
Dollar Volume1.03M
Avg. Volume324.78K
Avg. Weekly Volume246.61K
Avg. Monthly Volume365.03K
Avg. Quarterly Volume362.71K

Annexon Inc. (NASDAQ: ANNX) stock closed at 1.9 per share at the end of the most recent trading day (a -9.09% change compared to the prior day closing price) with a volume of 518.56K shares and market capitalization of 101.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. Annexon Inc. CEO is Douglas Love.

The one-year performance of Annexon Inc. stock is -68.24%, while year-to-date (YTD) performance is -63.25%. ANNX stock has a five-year performance of %. Its 52-week range is between 1.98 and 7.65, which gives ANNX stock a 52-week price range ratio of -1.41%

Annexon Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.87, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -46.54%, a ROC of -49.40% and a ROE of -55.21%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Annexon Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Annexon Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Annexon Inc. is Moderate Buy (1.63), with a target price of $18.57, which is +877.37% compared to the current price. The earnings rating for Annexon Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Annexon Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Annexon Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.86, ATR14 : 0.19, CCI20 : -167.28, Chaikin Money Flow : 0.10, MACD : -0.16, Money Flow Index : 65.48, ROC : -17.39, RSI : 33.86, STOCH (14,3) : 13.66, STOCH RSI : 0.00, UO : 46.69, Williams %R : -86.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Annexon Inc. in the last 12-months were: Douglas Love (Sold 6 571 shares of value $38 564 ), Jennifer Lew (Sold 1 908 shares of value $12 035 ), Love Douglas (Sold 6 571 shares of value $38 572 ), Michael Overdorf (Sold 1 645 shares of value $10 368 ), Muneer A. Satter (Buy at a value of $17 999 994), Overdorf Michael (Sold 1 645 shares of value $10 364 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (62.50 %)
5 (62.50 %)
5 (62.50 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
1 (12.50 %)
Hold
2 (25.00 %)
2 (25.00 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.63
Moderate Buy
1.63
Moderate Buy
1.63

Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.

CEO: Douglas Love

Telephone: +1 650 822-5500

Address: 180 Kimball Way, South San Francisco 94080, CA, US

Number of employees: 38

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

61%39%

 

TipRanks News for ANNX

Tue, 08 Aug 2023 10:25 GMT Annexon Biosciences (ANNX) Gets a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits